Publication | Closed Access

A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression

PsychiatryInn 00835MedicinePsychotropic MedicationNovel Antidepressant PeptideMajor DepressionPsychopharmacologyDepressionNeuropharmacologyPharmacotherapyPharmacologyNeuropeptides